Clinical TrialApr 22, 2026, 04:07 PM
Abivax to Present 9 Obefazimod Data Abstracts at DDW 2026
AI Summary
Abivax S.A. announced it will present nine scientific abstracts on its lead drug candidate, obefazimod, at the 2026 Digestive Disease Week from May 2-5. The presentations will highlight comprehensive efficacy, safety, and patient-reported outcomes from the Phase 3 ABTECT program for moderately to severely active ulcerative colitis. Additionally, preclinical anti-fibrotic activity will be showcased, reinforcing the company's confidence in obefazimod's potential to address patient and clinician needs.
Key Highlights
- Abivax to present 9 scientific abstracts on obefazimod at Digestive Disease Week 2026.
- Data includes comprehensive efficacy, safety, and patient-reported outcomes from Phase 3 ABTECT program.
- Presentations will cover obefazimod's anti-fibrotic activity in preclinical models.
- Focus on moderately to severely active ulcerative colitis treatment.
- Data reinforces confidence in obefazimod's potential for patients and clinicians.
Price Impact
More from ABVX